Anticancer Drugs and Cancer-Associated Thrombosis.

Anticancer therapies significantly increase the risk of venous thromboembolism, with various drugs linked to vascular toxicity in cancer patients.

• Why it matters: Vascular adverse events from anticancer drugs are often underestimated, creating gaps in risk assessment, prevention, and management that can compromise patient outcomes.
• What they did: The review analyzes evidence connecting anticancer drug exposure to venous thromboembolism, explores underlying mechanisms, and summarizes current guidelines for prevention and treatment, including arterial events.
• The result: Understanding these associations enables improved risk stratification and targeted interventions, advancing cardio-oncology practices to reduce thrombotic complications in cancer therapy.